Skip to main content
 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$440,752
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6

H.R. 247/S. 46, the Healthcare Affordability Act; extending advanced premium tax credits (APTCs); issues related to provider taxes.

Labor Health and Human Services Education, Homeland, Commerce, Justice, Science Appropriations; 340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Site-neutral payment policy; Issues related to hospital outpatient department payments; Issues related to DSH; Issues related to Medicaid supplemental payments; Issues related to Medicare payments; Issues related to Medicare Advantage reimbursement and prior authorization; Issues related to childrens medical care; issues related to rural health; Issues related to mental and behavioral health; enhanced Advanced Premium Tax Credits; issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act; Patients Deserve Price Tags Act

Labor Health and Human Services Education, Homeland, Commerce, Justice, Science Appropriations; 340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Site-neutral payment policy; Issues related to hospital outpatient department payments; Issues related to DSH; Issues related to Medicaid supplemental payments;Issues related to Medicare payments; Issues related to Medicare Advantage reimbursement and prior authorization; Issues related to childrens medical care; issues related to rural health; Issues related to mental and behavioral health; enhanced Advanced Premium Tax Credits; issues related to the implementation of H.R. 1, the One Big Beautiful Bill Act;

340B Program; Issues related to affordable prescription drugs; Equitable Community Access to Pharmacy Services Act; issues related to preventing and mitigating drug shortages;

H.R. 1, the One Big Beautiful Bill Act; EAPTC Extension

 Bills named in this filing 3
  • H.R. 247
    Health Care Affordability Act of 2025
  • S. 46
    Health Care Affordability Act of 2025
  • H.R. 1
    One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem